United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - zolmitriptan - orodispersible tablet - 2.5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - zolmitriptan - orodispersible tablet - 5mg

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - zolmitriptan - film coated tablet - 2.5 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - zolmitriptan - orodispersible tablet - 2.5 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - zolmitriptan - orodispersible tablet - 2.5 milligram - selective serotonin (5ht1) agonists

United States - English - NLM (National Library of Medicine)

amneal pharmaceuticals - zolmitriptan (unii: 2fs66th3yw) (zolmitriptan - unii:2fs66th3yw) - zolmitriptan 2.5 mg - zomig is indicated for the acute treatment of migraine with or without aura in adults. limitations of use zomig is contraindicated in patients with: risk summary there are no adequate data on the developmental risk associated with the use of zomig in pregnant women. in reproductive toxicity studies in rats and rabbits, oral administration of zolmitriptan to pregnant animals resulted in embryolethality and fetal abnormalities (malformations and variations) at clinically relevant exposures (see data). in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. the estimated rates of major birth defects (2.2%-2.9%) and miscarriage (17%) among deliveries to women with migraine are similar to rates reported in women without migraine. clinical considerations disease-associated maternal and/or embryo/fetal risk published data have suggested that women with migraine may be at increased risk of pree

United States - English - NLM (National Library of Medicine)

amneal pharmaceuticals - zolmitriptan (unii: 2fs66th3yw) (zolmitriptan - unii:2fs66th3yw) - zolmitriptan 5 mg - zomig nasal spray is indicated for the acute treatment of migraine with or without aura in adults and pediatric patients 12 years of age and older. limitations of use zomig is contraindicated in patients with: risk summary there are no adequate data on the developmental risk associated with the use of zomig in pregnant women. in reproductive toxicity studies in rats and rabbits, oral administration of zolmitriptan to pregnant animals resulted in embryolethality and fetal abnormalities (malformations and variations) at clinically relevant exposures (see data) . in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. the estimated rates of major birth defects (2.2%-2.9%) and miscarriage (17%) among deliveries to women with migraine are similar to rates reported in women without migraine. clinical considerations disease-associated maternal and/or embryo/fetal risk published data have sugges

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

arrow generics ltd - zolmitriptan - orodispersible tablet - 2.5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

arrow generics ltd - zolmitriptan - orodispersible tablet - 5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

zentiva pharma uk ltd - zolmitriptan - orodispersible tablet - 2.5mg